factor VIII

Factor VIII levels do not typically change throughout an individual's life.

Most of the patients in the study have been using the genetically engineered factor VIII for nearly two years.

The problem is that in these patients, factor VIII infusions are ineffective.

They may also have low levels of an additional factor known as factor VIII.

Those two genes are headed in the opposite direction from the rest of the factor VIII gene.

Injections of factor VIII derived from donated blood can control bleeding.

The inactivation of Factor VIII is not as well understood.

Factor VIII is one of several proteins that enable the blood to clot.

Factor VIII is not affected by liver disease.

Ten months after the treatment began, the investigators could no longer detect any Factor VIII in the patients' blood.

And their symptoms were alleviated when they injected themselves with purified factor VIII.

The factor VIII gene is on the tip of the X chromosome.

In either version, factor VIII is an expensive therapy, but the genetically engineered product comes at a premium price.

Like the new Factor VIII, these drugs unarguably represent substantial medical advances.

Factor VIII, which is essential for the treatment of hemophiliacs, is made from human blood plasma.

Hemophiliacs lack the protein factor VIII, which is essential for clotting blood.

Factor VIII essentially provides the missing ingredient without which hemophiliacs' blood cannot clot.

Acquired forms occur in the presence of elevated Factor VIII concentrations.

In humans, factor VIII is encoded by the F8 gene.

Desmopressin increases the amount of clotting factor VIII in your blood.

His blood also clots quickly, with a platelet level ten times normal, despite very low levels of factor VIII.

They made virtually no functioning factor VIII, the clotting protein that goes awry in the disease.

Until now, researchers had to examine the entire factor VIII gene for mutations, a slow and tedious process.

It also helps to stabilize factor VIII, the clotting protein often missing in hemophilia.

Screening now makes blood-derived factor VIII safe, but its supply is still constrained by the availability of blood.